These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 16386546)

  • 1. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of low doses of atorvastatin on the urinary peptide profile of kidney transplant patients.
    Pérez V; Navarro-Muñoz M; Bayés B; Lauzurica R; Pastor MC; Troya M; Bonet J; Ibernón M; Navarro M; Serra A; Núñez A; Romero R
    Transplant Proc; 2009; 41(6):2111-4. PubMed ID: 19715847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
    Navarro-Muñoz M; Bonet J; Bayés B; Lauzurica R; Blanco S; Romero R
    Transplant Proc; 2007 Sep; 39(7):2259-63. PubMed ID: 17889157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.
    Anagnostis P; Selalmatzidou D; Polyzos SA; Panagiotou A; Slavakis A; Panagiotidou A; Athyros VG; Karagiannis A; Mikhailidis DP; Kita M
    Int J Clin Pract; 2011 Jun; 65(6):679-83. PubMed ID: 21564441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
    Huptas S; Geiss HC; Otto C; Parhofer KG
    Am J Cardiol; 2006 Jul; 98(1):66-9. PubMed ID: 16784923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
    Ando H; Sugimoto K; Yanagihara H; Tsuruoka S; Saito T; Takamura T; Kaneko S; Fujimura A
    Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1012-7. PubMed ID: 18430053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study.
    Panichi V; Manca-Rizza G; Paoletti S; Taccola D; Consani C; Sbragia G; Mantuano E; Marchetti V; Carpi A; Barsotti G
    Biomed Pharmacother; 2006 Jun; 60(5):249-52. PubMed ID: 16740374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
    Wissing KM; Unger P; Ghisdal L; Broeders N; Berkenboom G; Carpentier Y; Abramowicz D
    Transplantation; 2006 Sep; 82(6):771-8. PubMed ID: 17006324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients.
    Tsouchnikas I; Dounousi E; Papakonstantinou S; Ioannou K; Kelesidis A; Kotzadamis N; Xanthopoulou K; Tsakiris D
    Nephrology (Carlton); 2009 Sep; 14(6):560-4. PubMed ID: 19422526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
    Ushiroyama T; Nosaka S; Ueki M
    Int J Cardiol; 2006 Oct; 113(1):66-75. PubMed ID: 16356567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Leslie SJ; Sasiela WJ; Szarek M; Libby P; Ganz P;
    Circulation; 2003 Sep; 108(13):1560-6. PubMed ID: 12975259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
    Blanco-Colio LM; Martín-Ventura JL; Gómez-Guerrero C; Masramon X; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Egido J
    Eur J Pharmacol; 2008 May; 586(1-3):259-65. PubMed ID: 18374327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.